{
    "clinical_study": {
        "@rank": "66998", 
        "arm_group": [
            {
                "arm_group_label": "AT", 
                "description": "Docetaxel 75 mg/m2, day 1 or paclitaxel 175mg/m2 day 1 plus Epirubicin 75 mg/m2, day 1 or doxorubicine 50mg/m2 day 1 for 6-8 cycles"
            }, 
            {
                "arm_group_label": "AT-NP", 
                "description": "docetaxel 75mg/m2,day 1 or paclitaxel 175mg/m2,day 1 plus doxorubicine 50mg/m2,day 1 or epirubicin 75mg/m2, day 1,for3-4 cycles then switch to  vinorelbine 25mg/m2, day 1 and day 8 plus cisplatinum 75mg/m2, day 1 for 3-4 cycles"
            }
        ], 
        "brief_summary": {
            "textblock": "The study purpose is to observe which neoadjuvant chemotherapy regimens is the better for\n      invasive breast cancer. The neoadjuvant chemotherapy regimen is sustained anthracyclines\n      plus taxanes or from anthracyclines plus taxanes to vinorelbine plus cisplatinum."
        }, 
        "brief_title": "Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The investigators hope to get preliminary results for the breast cancer patients who are\n      given different neoadjuvant chemothetapy regimens. The patients are randomized two\n      chemotherapy regimens. One is anthracyclines plus taxanes for 6-8 cycles,the other is\n      anthracyclines plus taxanes for 3-4 cycles ,then switch tovinorelbine plus cisplatinum for\n      3-4 cycles."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of invasive ductal or lobular breast cancer.\n\n          -  Previously untreated (no chemotherapy or hormonal therapy or radiation therapy)\n             invasive breast cancer.\n\n          -  no anti-Her2 therapy if HER2 positive ( defined as 3+ IHC or FISH positive)\n\n          -  Performance Status ECOG <2\n\n          -  Age > 18 years\n\n          -  Tumor > 2.0 cm by MRI and/or sonographic or clinical exam measurements.or Karnofsky\n             >50%\n\n          -  Lab test :\n\n               -  Absolute neutrophil count > 1,500/mm3\n\n                    -  Total Bilirubin \u2264 2\u00d7ULN\n\n                    -  AST and ALT \u2264 2.5\u00d7ULN\n\n               -  serum creatinine \u2264 1.5\u00d7ULN\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast feeding patients are excluded\n\n          -  stage \u2163 breast cancer\n\n          -  History of non-breast malignancies within the 5 years prior to study entry, except\n             for the following: carcinoma in situ of the cervix, carcinoma in situ of the\n             colon,melanoma in situ, and basal cell and squamous cell carcinomas of the skin\n\n          -  uncontrolled cardiac disease\n\n          -  Active infection or chronic infection requiring chronic suppressive antibiotics\n\n          -  History of hypersensitivity reaction to investigating drugs"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "diaganosis of invasive breast cancer, tumor size > 2.0cm by MRI or ultrasound or clinical\n        examination."
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732939", 
            "org_study_id": "307BCNeo-01"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 17, 2014", 
        "location": {
            "contact": {
                "last_name": "Tao Wang, MD", 
                "phone": "8610-66947430"
            }, 
            "contact_backup": {
                "last_name": "Shaohua ZHANG, MD", 
                "phone": "8610-66947173"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100071"
                }, 
                "name": "Hospital affiliated academy military medical science"
            }, 
            "investigator": {
                "last_name": "Zefei Jiang, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "2", 
        "overall_official": {
            "affiliation": "Hospital Affiliated Military Medical Science", 
            "last_name": "Zefei Jiang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "pathological complete response rate", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732939"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "clinical response rate, safety", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "source": "Hospital Affiliated to Military Medical Science, Beijing", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Affiliated to Military Medical Science, Beijing", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}